SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
G. Kyriakos, L. Quiles-Sánchez, A. Garmpi, Paraskevi Farmaki, Konstantina Kyre, S. Savvanis, Vasileios Antoniou, E. Memi
Current Cardiology Reviews